Section
Capital, M&A, and what biotech is worth this week.
Public market investors are rewarding Phase 2 clinical proof-of-concept in metabolic disease and ADCs while preclinical platform discovery engines face strict valuation discipline.
A major amendment to chemistry and manufacturing controls prompted a three-month FDA review extension, giving Pfizer additional runway in ATTR cardiomyopathy.
A dedicated radiopharmaceutical production complex in Indianapolis aims to secure domestic actinium-225 and lutetium-177 supplies as oncology demand surges.
CMS published maximum fair prices for the initial ten Part D blockbusters, forcing drug developers to re-evaluate small-molecule discovery timelines and indication stacking.
Phase 3 vutrisiran data demonstrated a 28% reduction in mortality risk, setting up an upstream gene-silencing showdown against Pfizer's incumbent oral blockbuster tafamidis.
Venture syndicates are concentrating capital into $100M+ Series A and B rounds for clinical-stage assets, leaving early-stage discovery platforms to navigate lean seed environments.